Lisa D. Macdonald
Dartmouth, NS, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 19, 2022
Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge.
Journal: NPJ vaccines
Published: July 03, 2018
A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.
Journal: The Journal of infectious diseases
Published: December 14, 2017
Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.
Journal: Human vaccines & immunotherapeutics
Published: September 22, 2017
Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo.
Journal: PloS one
Published: December 14, 2016
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
Journal: Oncoimmunology
Published: January 13, 2015
Using quality indicators to evaluate the effect of implementing an enhanced collaborative care model among a community, primary healthcare practice population.
Journal: Nursing leadership (Toronto, Ont.)
Published: September 27, 2012
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients.
Journal: Journal of translational medicine
Published: April 11, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026